Bispecific antibody and its clinical applications in cancer

查看全文 作　　者：Yuanfu [1]Xu;Chunzheng [1]Yang;Zhenping [1]Zhu

机构地区：[1]Chinese Acad Med Sci, Peking Union Med Coll, Inst Hematol, Natl Lab Expt Hematol, Tianjin 300020, Peoples R China

出　　处：《Chinese Science Bulletin》索引2001年第46卷第5期,共6页

基　　金：the State '863' High-Tech Program (Grant No. 102-09-03-03); by the Natural Science Foundation of Tianjin (GrantNo. 993803811). 摘　　要：Bispecific antibody (BsAb) usually consists of two different antigen-binding arms, by which it is capable of simultaneously binding to target cells and effector cells, and can directly mediate the killing of target cells by retargeting and activating effector cells. The development of BsAb research goes through three main stages: chemical cross-linking of murine-derived monoclonal antibody, hybrid hy-bridomas and engineered BsAb. Among them, engineered BsAb has more formats than the other two, such as diabody, ScdHLX, ScZip, ScCH3, ScFab and BsIgG, etc. Compared with former murine-derived BsAbs, engineered BsAb has lower immunogenicity and stronger penetrating capacity, and currently, some of them appear suitable for clinical application in yields and qualities. Up to now, several phase I and phase II clinical studies of BsAb, for instance, some (Fab’)2 and Diabodies, have been performed. Among those BsAbs, anti-CD3/anti-tumor BsAbs is most common, they not only can activate T cell and induce CD3AK 关键词：BISPECIFIC ANTIBODY GENETIC engineering TUMOR therapy.

相关文献

参考文献（41）
引证文献（7）
耦合文献（0）

参考文献(41)

引证文献(7)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Bispecific antibody and its clinical applications in cancer

参考文献(41)

引证文献(7)

用户提示